Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematologic Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,193 result(s) found for: Hematologic Disease. Displaying page 32 of 60.
    «« First « Previous 28  29  30  31  32  33  34  35  36  Next» Last»»
    EudraCT Number: 2015-004066-28 Sponsor Protocol Number: AMLSG2415 Start Date*: 2018-04-04
    Sponsor Name:University Hospital Ulm
    Full Title: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplas...
    Medical condition: Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome wi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004429-26 Sponsor Protocol Number: Atu027-I-02 Start Date*: 2013-02-25
    Sponsor Name:Silence Therapeutics GmbH
    Full Title: A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma
    Medical condition: Locally advanced or metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    17.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024298-37 Sponsor Protocol Number: ESOT/1/2010 Start Date*: 2011-03-28
    Sponsor Name:Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio
    Full Title: Early strong opiod treatment in cancer pain -Morphine vs weak opiods
    Medical condition: Tumor Pain, mild-moderate intensity (VAS 3-7)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005087-25 Sponsor Protocol Number: NeoPAN01-2013 Start Date*: 2014-04-01
    Sponsor Name:FUNDACION HOSPITAL DE MADRID
    Full Title: Gemcitabine plus nab-paclitaxel versus folfirinox as neoadjuvant treatment in patients with potentially resectable pancreatic carcinoma. NeoPAN Study
    Medical condition: Potentially resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001534-13 Sponsor Protocol Number: JAN13004-30 Start Date*: 2015-10-02
    Sponsor Name:SPHERIUM BIOMED S.L.
    Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation.
    Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10037763 Radiation mucositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001721-13 Sponsor Protocol Number: TAK-013/EC-302 Start Date*: 2005-01-24
    Sponsor Name:Takeda Europe R&D Center Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-000783-16 Sponsor Protocol Number: ML21531 Start Date*: 2008-06-18
    Sponsor Name:ROCHE SAS
    Full Title: Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast ca...
    Medical condition: Primary inflammatory HER2+ breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002480-15 Sponsor Protocol Number: M14REP Start Date*: 2014-10-15
    Sponsor Name:The Dutch Working Group on Immunotherapy of Oncology (WIN-O)
    Full Title: A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron E...
    Medical condition: BRAFV600-mutation positive patients with unresectable stage IIIc or IV melanoma.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001720-21 Sponsor Protocol Number: TAK-013/EC301 Start Date*: 2004-12-24
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    7 10014778 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001746-32 Sponsor Protocol Number: EORTC 21012 Start Date*: 2005-08-31
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy
    Medical condition: patients with refractory or relapsed advanced stages of mycosis fungoides (stage IIb, IVa, or Ivb)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028484 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001645-26 Sponsor Protocol Number: TMZ-FTM.CB.1 Start Date*: 2008-06-01
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients.
    Medical condition: Glioblastoma recurrent
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005190-36 Sponsor Protocol Number: 20050252 Start Date*: 2015-01-22
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors
    Medical condition: Solid Tumours
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065147 Malignant solid tumor LLT
    17.1 100000004864 10065252 Solid tumor LLT
    17.1 100000004864 10049280 Solid tumour LLT
    17.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000171-24 Sponsor Protocol Number: GCTSK004 Start Date*: 2016-07-12
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.
    Medical condition: Refractory histologically confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma germ cell tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004987-21 Sponsor Protocol Number: ONO-7579-01 Start Date*: 2017-09-13
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors
    Medical condition: Advanced solid tumors and Neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006197-88 Sponsor Protocol Number: FANCOSTEM-1 Start Date*: 2012-03-22
    Sponsor Name:Cristina Díaz de Heredia Rubio
    Full Title: Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent tra...
    Medical condition: Fanconi anemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10055206 Fanconi's anemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002768-15 Sponsor Protocol Number: GS-US-401-2076 Start Date*: 2018-02-26
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib with and without Obinutuzumab in Subjects wi...
    Medical condition: Adults with relapsed or refractory chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004165-58 Sponsor Protocol Number: GO39590 Start Date*: 2017-02-21
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR ME...
    Medical condition: Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002856-26 Sponsor Protocol Number: ADO-EP02(ML29328) Start Date*: 2016-12-19
    Sponsor Name:SRH Wald-Klinikum Gera GmbH
    Full Title: A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA
    Medical condition: Patients with large and/or recurrent resectable basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000469-35 Sponsor Protocol Number: GO29227 Start Date*: 2014-08-12
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRI...
    Medical condition: Inoperable locally advanced or metastatic triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027475 Metastatic breast cancer LLT
    17.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003909-42 Sponsor Protocol Number: GS-US-401-1958 Start Date*: 2016-09-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib with and without Obinutuzumab in Subjects with...
    Medical condition: Adults with relapsed or refractory chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 28  29  30  31  32  33  34  35  36  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:52:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA